Loading
Life sciences · Journal article
Molecular Medicine Reports · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of circadian biology and its potential role in squamous cell carcinoma pathogenesis and treatment. The authors acknowledge that evidence is predominantly preclinical with limited SCC-specific clinical data, positioning circadian regulation as an emerging area requiring translational research rather than established therapeutic principle.
Journal article. Squamous cell carcinoma, with emphasis on lung SCC; no specific patient cohort studied.
Circadian rhythms regulate cell proliferation, metabolism, DNA repair and immune function, pathways relevant to SCC biology Review emphasizes core clock genes (BMAL1, PER1-3, REV-ERBα/β) and their interactions with oncogenic and immune pathways in SCC Chronotherapy proposed as potential component of personalized SCC treatment, with particular focus on lung SCC
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize circadian regulation as an emerging mechanistic concept with potential therapeutic implications, but recognize that translational evidence from animal models and other cancer types does not yet support routine chronotherapy implementation in SCC management.
A review article summarizing mechanistic and preclinical evidence on circadian regulation in squamous cell carcinoma, explicitly acknowledging predominance of preclinical studies and limited clinical evidence, raising questions for future research rather than establishing clinical practice.
Clinicians should recognize circadian regulation as an emerging mechanistic concept with potential therapeutic implications, but recognize that translational evidence from animal models and other cancer types does not yet support routine chronotherapy implementation in SCC management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Squamous cell carcinoma (Scc) comprises a heterogeneous group of malignancies with distinct molecular characteristics, clinical behavior and therapeutic responses, highlighting the need for personalized treatment strategies.circadian rhythms regulate fundamental physiological processes, including cell proliferation, metabolism, dna repair and immune function, and emerging evidence suggests that circadian regulation may influence pathways relevant to Scc biology and treatment response.This review summarizes current knowledge on the role of circadian regulation in Scc, with particular emphasis on lung Scc, focusing on core clock genes, their interactions with oncogenic and immune-related pathways, and their therapeutic implications.We discuss current evidence supporting chronotherapy as a potential component of personalized Scc treatment while addressing important limitations, including the predominance of preclinical studies, limited SCC-specific clinical evidence and extrapolation from other tumor types.Finally, we outline key research priorities for translating circadian biology into clinical Scc management.Contents 1. introduction 2. System of the circadian clock 3. role of BMal1 in cancer 4. role of Per1-3 in cancer 5. role of reV-erBα/β in cancer 6. circadian clock in Scc 7. circadian clock in cancer therapy 8. chronotherapy in cancer treatment 9. limitations and research strategies 10. conclusion
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.